GNVC Description — GenVec Inc (DE)
GenVec is a clinical-stage biopharmaceutical company with a focus on utilizing its proprietary AdenoVerse gene delivery platform to develop a pipeline of therapeutics and vaccines. Co. is engaged in the design, testing and manufacture of adenoviral-based product candidates. Co.'s key product candidate, CGF166, is in a clinical study for the treatment of hearing loss and balance disorders. Co.'s combination of internal and partnered development programs address therapeutic areas, as well as vaccines against infectious diseases, including respiratory syncytial virus, herpes simplex virus, and malaria. In the area of animal health, Co. is developing vaccines against foot-and-mouth disease.
|
Free GNVC Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |